Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas
Background: The repertoire of salvage regimens for patients with WHO grade II and III gliomas recurring or progressing after surgery, radiotherapy and temozolomide chemotherapy is limited. Based on promising response and progression-free survival (PFS) data in recurrent glioblastoma, the use of beva...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2013
|
| In: |
European neurology
Year: 2013, Volume: 69, Issue: 2, Pages: 95-101 |
| ISSN: | 1421-9913 |
| DOI: | 10.1159/000343811 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1159/000343811 Verlag, lizenzpflichtig, Volltext: https://www.karger.com/Article/FullText/343811 
|
| Author Notes: | Katharina Seystahl, Benedikt Wiestler, Thomas Hundsberger, Caroline Happold, Wolfgang Wick, Michael Weller, Antje Wick |
| Summary: | Background: The repertoire of salvage regimens for patients with WHO grade II and III gliomas recurring or progressing after surgery, radiotherapy and temozolomide chemotherapy is limited. Based on promising response and progression-free survival (PFS) data in recurrent glioblastoma, the use of bevacizumab (BEV) has been extended to recurrent grade II/III gliomas. Methods: We retrospectively assessed the safety and efficacy of BEV alone or combined with irinotecan in 39 patients with recurrent grade II/III gliomas. Results: Both BEV monotherapy and its combination with irinotecan were well tolerated. Response rates were 26% as monotherapy and 33% in combination using Macdonald and RANO criteria. The median PFS was 4.2 months and the PFS rate at 6 months 29% for BEV alone, and 4.7 months and 42% for the combination. The median overall survival was 14.8 months for BEV monotherapy and 8.1 months for the combination. Outcome after failure of BEV was better when patients continued BEV beyond progression. Conclusion: BEV has limited activity in recurrent grade II/III gliomas. The additional value of irinotecan remains questionable. Prospective studies with BEV-free control groups are required to better define the role of BEV among the limited options in patients with recurrent grade II/III gliomas. |
|---|---|
| Item Description: | Published online: November 22, 2012 Gesehen am 19.08.2021 |
| Physical Description: | Online Resource |
| ISSN: | 1421-9913 |
| DOI: | 10.1159/000343811 |